Ponatinib Active in Patients with CML and Ph+ ALL Resistant/Intolerant to Dasatinib or Nilotinib or Who Have the T315I Mutation

Share this content:
Ponatinib Active in Patients with CML and Ph+ ALL Resistant/Intolerant to Dasatinib or Nilotinib or Who Have the T315I Mutation
Ponatinib Active in Patients with CML and Ph+ ALL Resistant/Intolerant to Dasatinib or Nilotinib or Who Have the T315I Mutation

CME

Program Description:

The potent, oral, pan-BCR-ABL inhibitor ponatinib has demonstrated robust antileukemic activity in a heavily pretreated population of patients with chronic myelogenous leukemia or Ph positive (Ph+) acute lymphoblastic leukemia who are resistant or intolerant to dasatinib or nilotinib or have the T315I mutation, according to a pivotal trial reported at the 2012 Annual Meeting of the American Society of Clinical Oncology.

INTENDED AUDIENCE:

Physicians, nurse practitioners, physician assistants, nurses, and other healthcare providers who manage patients with CML/ALL

Activity Objectives:

After participating in this educational activity, participants should be better able to:

  • Analyze recent clinical advances in the management of Philadelphia-positive acute lymphoblastic leukemia, including second-generation tyrosine kinase inhibitors (TKIs) and multi-kinase inhibitors

  • Evaluate recent clinical advances in the treatment of intolerant/resistant chronic myeloid leukemia, including the use of generation TKIs

Click Next to begin reading the activity.

Page 1 of 4

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs